On June 3, 2026, Elsevier released its official 2025 CiteScore data. We are happy to share that Exploration of Targeted Anti-tumor Therapy (ETAT) has achieved the 2025 CiteScore of 5.4, with a significant increase of 74.19% compared with last year. This marks an important breakthrough for our journal.

With this improvement, ETAT has entered the Q2 quartile in the oncology category. It now ranks 140th among 428 oncology journals worldwide, which means our academic recognition keeps growing steadily. Over the past four years, ETAT’s influence has kept rising year by year. The CiteScore has grown consistently: 1.7 in 2022, 2.8 in 2023, 3.1 in 2024, and 5.4 in 2025. For more details, please visit ETAT's page on Scopus: https://www.scopus.com/sourceid/21101088220

This steady progress would not be possible without the professional work of our Editorial Board Members, the careful evaluation of our reviewers, and the continuous support of all authors. We sincerely thank everyone who has contributed to the development of ETAT.

ETAT focuses on the latest research and clinical progress in targeted anti-tumor therapy, aiming to provide a reliable academic platform for researchers and clinical practitioners. The journal is currently indexed in major academic databases, including Scopus, PubMed/PMC and Google Scholar. We welcome researchers and medical scholars from all over the world to submit your valuable work to ETAT.